Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Conditions
Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 24 locations
View Trial Details
Completed

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

NCT02244125

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • CHRU Hopital Sud Amiens, France
  • Centre Hospitalier de la côte Basque Bayonne, France
  • Hôpital Avicenne Bobigny, France
  • ICH - Hôpital A. Morvan Brest, France
View all 30 locations
View Trial Details
Completed

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT02588651

Conditions
Adult T-Cell Leukemia/Lymphoma, Angioimmunoblastic T-cell Lymphoma, Enteropathy Associated T-cell Lymphoma, +22 more
Locations
  • Wayne State University, Karmanos Cancer Institute Detroit, Michigan, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

NCT07145125

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
Locations
  • CH de la Côte Basque, service Hématologie Clinique Bayonne, France
  • CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire Bordeaux, France
  • CHU de Caen, service Hématologie Clinique Caen, France
  • Institut Paoli Calmettes, service Hématologie Clinique Marseille, France
View Trial Details
Completed

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

NCT04172246

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +28 more
Locations
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Toyohashi Municipal Hospital Toyohashishi, Aichi-ken, Japan
  • Chiba Cancer Center Chiba, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Ehime, Japan
View all 15 locations
View Trial Details
Completed

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

NCT01139970

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, +45 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details

Related conditions